More evidence necessary to support amyloid imaging for Alzheimer's

A review of current literature in JAMA Internal Medicine on amyloid-beta PET imaging for Alzheimer's disease (AD) has found insufficient evidence that it leads to better clinical outcomes.

"The available evidence on [amyloid-beta] PET has many limitations beyond the sparse number of studies," wrote Steven D. Pearson, M.D., and colleagues from the Institute for Clinical and Economic Review in Boston. "Nearly all the studies have evaluated diagnostic performance, not whether test results improve clinical management or patient outcomes. Many potential benefits and harms of the imaging have not been evaluated."

The Center for Medicare & Medicaid Services recently released a coverage decision denying coverage for amyloid-beta ET scans in routine clinical care. Article

Suggested Articles

An assessment looking at 12 health systems that allow patients to download their health records to their smartphones via APIs finds modest uptake.

The National Institutes of Health-led All of Us precision medicine health research database project has enrolled 230,000 participants.

Hospitals must pursue a deliberate strategy for managing their public image—and a powerful tool for doing so is inpatient clinical data registries.